Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure
Clinical trial NCT07708194 · RECRUITING
Trial details
- NCT number
- NCT07708194
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-06-23
- Primary completion
- 2027-02-01
- Enrollment
- 94
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.